% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Schildberg:128256,
author = {C. W. Schildberg and M. L. Abba$^*$ and S. Merkel and A.
Agaimy and A. Dimmler and A. Schlabrakowski and R. Croner
and J. H. Leupold$^*$ and W. Hohenberger and H.
Allgayer$^*$},
title = {{G}astric cancer patients less than 50 years of age exhibit
significant downregulation of {E}-cadherin and {CDX}2
compared to older reference populations.},
journal = {Advances in medical sciences},
volume = {59},
number = {1},
issn = {1896-1126},
address = {Amsterdam [u.a.]},
publisher = {Elsevier},
reportid = {DKFZ-2017-04273},
pages = {142 - 146},
year = {2014},
abstract = {There is an increasing need to identify molecular markers,
which can be used to prognosticate patient populations in
gastric cancer. Whereas a significant number have been
identified, very few have been characterized in the context
of their ability to discriminate between young and old age
groups in which a survival difference clearly exists.In this
study, using immunohistochemistry, we evaluated three
markers with proven involvement in gastric cancer. The p53
tumor suppressor, the cell adhesion glycoprotein epithelial
cadherin (CDH1) and the caudal-related homeobox
transcription factor (CDX2) all of these have important
roles in the aetiopathogenesis and/or progression of gastric
cancer.After adjustments for TNM stage, tumor grade,
histopathological characteristics (Lauren classification),
we found significant differences in the expression of these
proteins, particularly E-cadherin and CDX2 between young and
elderly patients. However, these differences did not amount
to a significant difference in survival.This study
demonstrates that the protein expression of p53, CDH1 and
CDX2 significantly discriminates young patients with gastric
cancer who have a better prognostic outlook from older
patients, but this difference in expression does not
contribute to a survival benefit.},
keywords = {Biomarkers, Tumor (NLM Chemicals) / CDX2 Transcription
Factor (NLM Chemicals) / CDX2 protein, human (NLM Chemicals)
/ Cadherins (NLM Chemicals) / Homeodomain Proteins (NLM
Chemicals)},
cin = {G360},
ddc = {610},
cid = {I:(DE-He78)G360-20160331},
pnm = {317 - Translational cancer research (POF3-317)},
pid = {G:(DE-HGF)POF3-317},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:24797991},
doi = {10.1016/j.advms.2014.03.002},
url = {https://inrepo02.dkfz.de/record/128256},
}